Path ID: DB00555_MESH_D004827_2
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:C047781 | lamotrigine | Drug |
| UniProt:Q15878 | Voltage-dependent R-type calcium channel subunit alpha-1E | Protein |
| reactome:R-HSA-112308 | Presynaptic depolarization and calcium channel opening | Pathway |
| GO:0007268 | chemical synaptic transmission | BiologicalProcess |
| GO:0061535 | glutamate secretion, neurotransmission | BiologicalProcess |
| HP:0020219 | Motor seizure | PhenotypicFeature |
| MESH:D004827 | Epilepsy | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Lamotrigine | NEGATIVELY REGULATES | Voltage-Dependent R-Type Calcium Channel Subunit Alpha-1E |
| Voltage-Dependent R-Type Calcium Channel Subunit Alpha-1E | PARTICIPATES IN | Presynaptic Depolarization And Calcium Channel Opening |
| Voltage-Dependent R-Type Calcium Channel Subunit Alpha-1E | PARTICIPATES IN | Presynaptic Depolarization And Calcium Channel Opening |
| Presynaptic Depolarization And Calcium Channel Opening | POSITIVELY CORRELATED WITH | Chemical Synaptic Transmission |
| Chemical Synaptic Transmission | POSITIVELY CORRELATED WITH | Glutamate Secretion, Neurotransmission |
| Glutamate Secretion, Neurotransmission | POSITIVELY CORRELATED WITH | Motor Seizure |
| Motor Seizure | POSITIVELY CORRELATED WITH | Epilepsy |
Comment: This drug may also affect GABA-mediated synaptic transmission as listed by DrugBank (https://go.drugbank.com/drugs/DB00555#BE0000013). However, this is contentious and if the drug does modulate GABA it’s not known whether it is as agonist or antagonist due to conflicting data (at best it would be a weak modulation seen in animal models only). Note that the drug could be contraindicated for treatment of seizures as it can exacerbate them, specially the myoclonic type (https://pubmed.ncbi.nlm.nih.gov/9596203/).
Reference: